Kailera Therapeutics, Inc.
KLRA Nasdaq
SEC CIK 2096997
Follow Kailera Therapeutics
Weekly email: filings, results
Net income
−$95.7M
−141.4% vs same quarter last year
EPS, diluted
−$0.74
Operating cash flow
−$133.7M
−350.1% vs same quarter last year
Operating income
−$106.3M
−165.1% vs same quarter last year
Source: SEC XBRL filings · latest filing